CN108743916A - 用于预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物 - Google Patents

Info

Publication number

CN108743916A

CN108743916A CN201810587683.3A CN201810587683A CN108743916A CN 108743916 A CN108743916 A CN 108743916A CN 201810587683 A CN201810587683 A CN 201810587683A CN 108743916 A CN108743916 A CN 108743916A

Authority

CN

China

Prior art keywords

peptide

amino acid

seq

leu

ala

Prior art date

2008-01-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 975
• 230000003405 preventing effect Effects 0.000 title claims abstract description 46
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 112
• 201000010099 disease Diseases 0.000 title claims description 104
• 230000004224 protection Effects 0.000 title claims description 97
• 230000000451 tissue damage Effects 0.000 title claims description 60
• 231100000827 tissue damage Toxicity 0.000 title claims description 60
• 230000008520 organization Effects 0.000 title description 68
• 238000000926 separation method Methods 0.000 claims abstract description 130
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 108
• 201000011510 cancer Diseases 0.000 claims abstract description 59
• 230000002669 organ and tissue protective effect Effects 0.000 claims abstract description 39
• 239000003814 drug Substances 0.000 claims abstract description 23
• 229940079593 drug Drugs 0.000 claims abstract description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
• 230000001613 neoplastic effect Effects 0.000 claims abstract description 13
• 206010006895 Cachexia Diseases 0.000 claims abstract 4
• 150000001413 amino acids Chemical class 0.000 claims description 241
• 210000004027 cell Anatomy 0.000 claims description 194
• 230000000694 effects Effects 0.000 claims description 131
• 238000000034 method Methods 0.000 claims description 101
• 125000000539 amino acid group Chemical group 0.000 claims description 95
• 210000001519 tissue Anatomy 0.000 claims description 78
• 208000024891 symptom Diseases 0.000 claims description 55
• 238000011282 treatment Methods 0.000 claims description 51
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
• 238000006467 substitution reaction Methods 0.000 claims description 37
• 206010061218 Inflammation Diseases 0.000 claims description 35
• 230000004054 inflammatory process Effects 0.000 claims description 35
• 210000000056 organ Anatomy 0.000 claims description 33
• 108010005636 polypeptide C Proteins 0.000 claims description 31
• -1 SEQ ID NO:281) Proteins 0.000 claims description 29
• 231100000167 toxic agent Toxicity 0.000 claims description 26
• 239000003440 toxic substance Substances 0.000 claims description 26
• 239000002253 acid Substances 0.000 claims description 24
• 239000000203 mixture Substances 0.000 claims description 23
• 238000012217 deletion Methods 0.000 claims description 21
• 230000037430 deletion Effects 0.000 claims description 21
• 210000004369 blood Anatomy 0.000 claims description 18
• 239000008280 blood Substances 0.000 claims description 18
• 230000002209 hydrophobic effect Effects 0.000 claims description 17
• 230000008859 change Effects 0.000 claims description 16
• 108020004707 nucleic acids Proteins 0.000 claims description 15
• 102000039446 nucleic acids Human genes 0.000 claims description 15
• 150000007523 nucleic acids Chemical class 0.000 claims description 15
• 210000003169 central nervous system Anatomy 0.000 claims description 9
• 229920001223 polyethylene glycol Polymers 0.000 claims description 7
• 229920001184 polypeptide Polymers 0.000 claims description 7
• 210000002345 respiratory system Anatomy 0.000 claims description 7
• 101800005149 Peptide B Proteins 0.000 claims description 6
• 229910052799 carbon Inorganic materials 0.000 claims description 6
• 239000013604 expression vector Substances 0.000 claims description 6
• 108010091748 peptide A Proteins 0.000 claims description 6
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 5
• 241000124008 Mammalia Species 0.000 claims description 5
• 230000002708 enhancing effect Effects 0.000 claims description 5
• 108010011901 glutaminyl-glutamyl-glutaminyl-leucyl-glutamyl-arginyl-alanyl-leucyl-asparagyl-seryl-serine Proteins 0.000 claims description 5
• 230000001976 improved effect Effects 0.000 claims description 5
• 230000002093 peripheral effect Effects 0.000 claims description 5
• 101150098072 20 gene Proteins 0.000 claims description 4
• 206010019280 Heart failures Diseases 0.000 claims description 4
• 239000002202 Polyethylene glycol Substances 0.000 claims description 4
• 210000000481 breast Anatomy 0.000 claims description 4
• 238000002512 chemotherapy Methods 0.000 claims description 4
• PCFGFYKGPMQDBX-FEKONODYSA-N 78355-50-7 Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 PCFGFYKGPMQDBX-FEKONODYSA-N 0.000 claims description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
• 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
• 208000007502 anemia Diseases 0.000 claims description 3
• 229910052731 fluorine Inorganic materials 0.000 claims description 3
• 201000006370 kidney failure Diseases 0.000 claims description 3
• 108010069653 peptide E (adrenal medulla) Proteins 0.000 claims description 3
• 238000001959 radiotherapy Methods 0.000 claims description 3
• 208000030507 AIDS Diseases 0.000 claims description 2
• 206010003694 Atrophy Diseases 0.000 claims description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
• 206010014561 Emphysema Diseases 0.000 claims description 2
• 230000037444 atrophy Effects 0.000 claims description 2
• 210000002249 digestive system Anatomy 0.000 claims description 2
• 235000013372 meat Nutrition 0.000 claims description 2
• 229910052700 potassium Inorganic materials 0.000 claims description 2
• 210000004872 soft tissue Anatomy 0.000 claims description 2
• 230000001612 cachectic effect Effects 0.000 claims 2
• 208000037487 Endotoxemia Diseases 0.000 claims 1
• 206010019663 Hepatic failure Diseases 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 210000005095 gastrointestinal system Anatomy 0.000 claims 1
• 210000005096 hematological system Anatomy 0.000 claims 1
• 208000007903 liver failure Diseases 0.000 claims 1
• 231100000835 liver failure Toxicity 0.000 claims 1
• 239000002777 nucleoside Substances 0.000 claims 1
• 125000003835 nucleoside group Chemical group 0.000 claims 1
• 208000008128 pulmonary tuberculosis Diseases 0.000 claims 1
• 229940024606 amino acid Drugs 0.000 description 204
• 235000001014 amino acid Nutrition 0.000 description 197
• 230000006378 damage Effects 0.000 description 80
• 108090000394 Erythropoietin Proteins 0.000 description 69
• 102000003951 Erythropoietin Human genes 0.000 description 68
• 229940105423 erythropoietin Drugs 0.000 description 65
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 64
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 55
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 51
• 241000700159 Rattus Species 0.000 description 50
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 44
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 40
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 40
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 37
• 238000012360 testing method Methods 0.000 description 37
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 36
• 108090000623 proteins and genes Proteins 0.000 description 36
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 34
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 34
• 208000011580 syndromic disease Diseases 0.000 description 34
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 33
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 31
• 150000001875 compounds Chemical class 0.000 description 31
• 102000004127 Cytokines Human genes 0.000 description 30
• 108090000695 Cytokines Proteins 0.000 description 30
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 30
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 29
• 208000027418 Wounds and injury Diseases 0.000 description 29
• 238000002474 experimental method Methods 0.000 description 29
• 230000004044 response Effects 0.000 description 29
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 26
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 26
• 241001465754 Metazoa Species 0.000 description 26
• 241000699666 Mus <mouse, genus> Species 0.000 description 26
• 102000004169 proteins and genes Human genes 0.000 description 26
• 239000003795 chemical substances by application Substances 0.000 description 25
• 238000003786 synthesis reaction Methods 0.000 description 23
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 22
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 22
• 230000014509 gene expression Effects 0.000 description 22
• 235000018102 proteins Nutrition 0.000 description 22
• 239000002585 base Substances 0.000 description 21
• 230000002757 inflammatory effect Effects 0.000 description 20
• 230000015572 biosynthetic process Effects 0.000 description 19
• NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Natural products NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 19
• 102000005962 receptors Human genes 0.000 description 19
• 108020003175 receptors Proteins 0.000 description 19
• 238000000338 in vitro Methods 0.000 description 18
• 208000014674 injury Diseases 0.000 description 18
• 108020004414 DNA Proteins 0.000 description 17
• 241000700605 Viruses Species 0.000 description 17
• 238000001727 in vivo Methods 0.000 description 17
• 230000002265 prevention Effects 0.000 description 17
• 230000005855 radiation Effects 0.000 description 17
• 206010020751 Hypersensitivity Diseases 0.000 description 16
• 239000012267 brine Substances 0.000 description 16
• 239000002609 medium Substances 0.000 description 16
• 210000005036 nerve Anatomy 0.000 description 16
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
• 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 15
• 206010052428 Wound Diseases 0.000 description 15
• 210000002216 heart Anatomy 0.000 description 15
• 239000012071 phase Substances 0.000 description 15
• 230000004663 cell proliferation Effects 0.000 description 14
• 239000000126 substance Substances 0.000 description 14
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 13
• 238000010171 animal model Methods 0.000 description 13
• 239000013043 chemical agent Substances 0.000 description 13
• 208000024780 Urticaria Diseases 0.000 description 12
• 230000001154 acute effect Effects 0.000 description 12
• 208000026935 allergic disease Diseases 0.000 description 12
• 210000004072 lung Anatomy 0.000 description 12
• 230000004048 modification Effects 0.000 description 12
• 238000012986 modification Methods 0.000 description 12
• 210000003491 skin Anatomy 0.000 description 12
• 241000894006 Bacteria Species 0.000 description 11
• 229910021529 ammonia Inorganic materials 0.000 description 11
• 210000004556 brain Anatomy 0.000 description 11
• 230000022131 cell cycle Effects 0.000 description 11
• 210000003743 erythrocyte Anatomy 0.000 description 11
• 230000000302 ischemic effect Effects 0.000 description 11
• MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 11
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
• 230000002411 adverse Effects 0.000 description 10
• 230000007815 allergy Effects 0.000 description 10
• 238000001514 detection method Methods 0.000 description 10
• 210000001508 eye Anatomy 0.000 description 10
• 239000001963 growth medium Substances 0.000 description 10
• 229960001340 histamine Drugs 0.000 description 10
• 108050006400 Cyclin Proteins 0.000 description 9
• QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 9
• 108091006116 chimeric peptides Proteins 0.000 description 9
• 230000006870 function Effects 0.000 description 9
• 210000004209 hair Anatomy 0.000 description 9
• 230000001965 increasing effect Effects 0.000 description 9
• 210000003734 kidney Anatomy 0.000 description 9
• 230000009467 reduction Effects 0.000 description 9
• 230000010410 reperfusion Effects 0.000 description 9
• 206010006187 Breast cancer Diseases 0.000 description 8
• 208000026310 Breast neoplasm Diseases 0.000 description 8
• 206010009944 Colon cancer Diseases 0.000 description 8
• 239000003124 biologic agent Substances 0.000 description 8
• 239000000090 biomarker Substances 0.000 description 8
• 210000004204 blood vessel Anatomy 0.000 description 8
• 230000001684 chronic effect Effects 0.000 description 8
• 206010015037 epilepsy Diseases 0.000 description 8
• 150000002148 esters Chemical class 0.000 description 8
• 230000004968 inflammatory condition Effects 0.000 description 8
• 208000032839 leukemia Diseases 0.000 description 8
• 239000003446 ligand Substances 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 229910052697 platinum Inorganic materials 0.000 description 8
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 230000004083 survival effect Effects 0.000 description 8
• 102000001554 Hemoglobins Human genes 0.000 description 7
• 108010054147 Hemoglobins Proteins 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 239000000460 chlorine Substances 0.000 description 7
• 229910052801 chlorine Inorganic materials 0.000 description 7
• 238000005534 hematocrit Methods 0.000 description 7
• 230000006698 induction Effects 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 230000009545 invasion Effects 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 238000010172 mouse model Methods 0.000 description 7
• 231100000765 toxin Toxicity 0.000 description 7
• 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 6
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
• 102000016736 Cyclin Human genes 0.000 description 6
• 208000001953 Hypotension Diseases 0.000 description 6
• 108010002386 Interleukin-3 Proteins 0.000 description 6
• 102000000646 Interleukin-3 Human genes 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 6
• 208000006011 Stroke Diseases 0.000 description 6
• 102000036693 Thrombopoietin Human genes 0.000 description 6
• 108010041111 Thrombopoietin Proteins 0.000 description 6
• 208000006673 asthma Diseases 0.000 description 6
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
• 210000001772 blood platelet Anatomy 0.000 description 6
• 239000005482 chemotactic factor Substances 0.000 description 6
• 208000029742 colonic neoplasm Diseases 0.000 description 6
• 108010057085 cytokine receptors Proteins 0.000 description 6
• 102000003675 cytokine receptors Human genes 0.000 description 6
• 230000034994 death Effects 0.000 description 6
• 231100000517 death Toxicity 0.000 description 6
• 230000005284 excitation Effects 0.000 description 6
• 210000004907 gland Anatomy 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 230000003394 haemopoietic effect Effects 0.000 description 6
• LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 6
• 208000015181 infectious disease Diseases 0.000 description 6
• 210000002540 macrophage Anatomy 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 229910052760 oxygen Inorganic materials 0.000 description 6
• 239000001301 oxygen Substances 0.000 description 6
• 230000007170 pathology Effects 0.000 description 6
• 210000002307 prostate Anatomy 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 239000003053 toxin Substances 0.000 description 6
• 108700012359 toxins Proteins 0.000 description 6
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
• 208000019155 Radiation injury Diseases 0.000 description 5
• 206010047700 Vomiting Diseases 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 230000027455 binding Effects 0.000 description 5
• 230000012820 cell cycle checkpoint Effects 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 230000001276 controlling effect Effects 0.000 description 5
• 206010014599 encephalitis Diseases 0.000 description 5
• 210000002683 foot Anatomy 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 210000001035 gastrointestinal tract Anatomy 0.000 description 5
• 210000000936 intestine Anatomy 0.000 description 5
• 208000012866 low blood pressure Diseases 0.000 description 5
• 230000003211 malignant effect Effects 0.000 description 5
• 210000004962 mammalian cell Anatomy 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 210000004126 nerve fiber Anatomy 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 230000002207 retinal effect Effects 0.000 description 5
• 239000000523 sample Substances 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 210000000278 spinal cord Anatomy 0.000 description 5
• 210000000130 stem cell Anatomy 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
• 206010069747 Burkholderia mallei infection Diseases 0.000 description 4
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 4
• 206010010904 Convulsion Diseases 0.000 description 4
• 206010012735 Diarrhoea Diseases 0.000 description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
• 206010013975 Dyspnoeas Diseases 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 241000196324 Embryophyta Species 0.000 description 4
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 4
• 241000233866 Fungi Species 0.000 description 4
• 201000003641 Glanders Diseases 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 206010021143 Hypoxia Diseases 0.000 description 4
• 108010002352 Interleukin-1 Proteins 0.000 description 4
• 102000000589 Interleukin-1 Human genes 0.000 description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
• STNJBCKSHOAVAJ-UHFFFAOYSA-N Methacrolein Chemical compound CC(=C)C=O STNJBCKSHOAVAJ-UHFFFAOYSA-N 0.000 description 4
• 241000699660 Mus musculus Species 0.000 description 4
• 208000002193 Pain Diseases 0.000 description 4
• 102100036154 Platelet basic protein Human genes 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• 208000005718 Stomach Neoplasms Diseases 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 206010047115 Vasculitis Diseases 0.000 description 4
• 241000607479 Yersinia pestis Species 0.000 description 4
• 208000030961 allergic reaction Diseases 0.000 description 4
• 150000001408 amides Chemical class 0.000 description 4
• 230000006907 apoptotic process Effects 0.000 description 4
• RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical compound [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 description 4
• 208000010668 atopic eczema Diseases 0.000 description 4
• 230000012292 cell migration Effects 0.000 description 4
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 239000000539 dimer Substances 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
• 239000007789 gas Substances 0.000 description 4
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 201000005202 lung cancer Diseases 0.000 description 4
• 208000020816 lung neoplasm Diseases 0.000 description 4
• 210000002751 lymph Anatomy 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 208000010125 myocardial infarction Diseases 0.000 description 4
• 229960003753 nitric oxide Drugs 0.000 description 4
• 230000036407 pain Effects 0.000 description 4
• 210000000496 pancreas Anatomy 0.000 description 4
• 230000000144 pharmacologic effect Effects 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 230000006798 recombination Effects 0.000 description 4
• 238000005215 recombination Methods 0.000 description 4
• 210000001525 retina Anatomy 0.000 description 4
• 230000035939 shock Effects 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 238000011830 transgenic mouse model Methods 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 238000001262 western blot Methods 0.000 description 4
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 3
• 208000001395 Acute radiation syndrome Diseases 0.000 description 3
• 208000003829 American Hemorrhagic Fever Diseases 0.000 description 3
• 206010003497 Asphyxia Diseases 0.000 description 3
• 241000193830 Bacillus <bacterium> Species 0.000 description 3
• 241000193738 Bacillus anthracis Species 0.000 description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 206010008190 Cerebrovascular accident Diseases 0.000 description 3
• 108091006146 Channels Proteins 0.000 description 3
• 208000016192 Demyelinating disease Diseases 0.000 description 3
• 208000000059 Dyspnea Diseases 0.000 description 3
• 208000004232 Enteritis Diseases 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 208000032612 Glial tumor Diseases 0.000 description 3
• 206010018338 Glioma Diseases 0.000 description 3
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 3
• 241000175212 Herpesvirales Species 0.000 description 3
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 3
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 241000204031 Mycoplasma Species 0.000 description 3
• 206010028813 Nausea Diseases 0.000 description 3
• 206010028851 Necrosis Diseases 0.000 description 3
• 108010025020 Nerve Growth Factor Proteins 0.000 description 3
• 102000015336 Nerve Growth Factor Human genes 0.000 description 3
• 102100035411 Neuroglobin Human genes 0.000 description 3
• 108010026092 Neuroglobin Proteins 0.000 description 3
• 206010030113 Oedema Diseases 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 206010035148 Plague Diseases 0.000 description 3
• 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 3
• 206010068142 Radiation sickness syndrome Diseases 0.000 description 3
• 206010063837 Reperfusion injury Diseases 0.000 description 3
• 208000025747 Rheumatic disease Diseases 0.000 description 3
• 241000606701 Rickettsia Species 0.000 description 3
• 206010039491 Sarcoma Diseases 0.000 description 3
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 3
• 241000282898 Sus scrofa Species 0.000 description 3
• 206010043255 Tendonitis Diseases 0.000 description 3
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
• 241000723873 Tobacco mosaic virus Species 0.000 description 3
• 206010052779 Transplant rejections Diseases 0.000 description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
• 210000001015 abdomen Anatomy 0.000 description 3
• 230000000172 allergic effect Effects 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 239000005557 antagonist Substances 0.000 description 3
• 230000002424 anti-apoptotic effect Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 206010006451 bronchitis Diseases 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 238000007385 chemical modification Methods 0.000 description 3
• XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
• 230000036461 convulsion Effects 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 238000010586 diagram Methods 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 3
• 235000013305 food Nutrition 0.000 description 3
• 229940084434 fungoid Drugs 0.000 description 3
• 230000000799 fusogenic effect Effects 0.000 description 3
• 206010017758 gastric cancer Diseases 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 208000019622 heart disease Diseases 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 238000012744 immunostaining Methods 0.000 description 3
• 238000002513 implantation Methods 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 208000002551 irritable bowel syndrome Diseases 0.000 description 3
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 230000000116 mitigating effect Effects 0.000 description 3
• 210000000214 mouth Anatomy 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 230000017074 necrotic cell death Effects 0.000 description 3
• 230000014511 neuron projection development Effects 0.000 description 3
• JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 3
• 210000000578 peripheral nerve Anatomy 0.000 description 3
• 230000000505 pernicious effect Effects 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 238000011552 rat model Methods 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 208000017520 skin disease Diseases 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 201000011549 stomach cancer Diseases 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 241000712461 unidentified influenza virus Species 0.000 description 3
• 210000002700 urine Anatomy 0.000 description 3
• 210000004291 uterus Anatomy 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• 230000008673 vomiting Effects 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 230000029663 wound healing Effects 0.000 description 3
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
• HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 2
• HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 241000120516 African horse sickness virus Species 0.000 description 2
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 2
• VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 206010002329 Aneurysm Diseases 0.000 description 2
• 241000712892 Arenaviridae Species 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 241001225321 Aspergillus fumigatus Species 0.000 description 2
• 206010003571 Astrocytoma Diseases 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 208000004429 Bacillary Dysentery Diseases 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 241001148111 Brucella suis Species 0.000 description 2
• 206010006811 Bursitis Diseases 0.000 description 2
• 101150012716 CDK1 gene Proteins 0.000 description 2
• 244000025254 Cannabis sativa Species 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 206010007558 Cardiac failure chronic Diseases 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 2
• 208000005243 Chondrosarcoma Diseases 0.000 description 2
• 241000710777 Classical swine fever virus Species 0.000 description 2
• 241000193468 Clostridium perfringens Species 0.000 description 2
• 241000223203 Coccidioides Species 0.000 description 2
• 241000223205 Coccidioides immitis Species 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 206010010741 Conjunctivitis Diseases 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
• 108010069514 Cyclic Peptides Proteins 0.000 description 2
• 102000001189 Cyclic Peptides Human genes 0.000 description 2
• 102100034126 Cytoglobin Human genes 0.000 description 2
• 108010053020 Cytoglobin Proteins 0.000 description 2
• 230000006820 DNA synthesis Effects 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• 206010012689 Diabetic retinopathy Diseases 0.000 description 2
• XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 101100256910 Drosophila melanogaster sick gene Proteins 0.000 description 2
• 241001115402 Ebolavirus Species 0.000 description 2
• 241000606675 Ehrlichia ruminantium Species 0.000 description 2
• 208000005189 Embolism Diseases 0.000 description 2
• 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 206010015150 Erythema Diseases 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 108010074864 Factor XI Proteins 0.000 description 2
• 208000001640 Fibromyalgia Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 102000003869 Frataxin Human genes 0.000 description 2
• 108090000217 Frataxin Proteins 0.000 description 2
• 230000010190 G1 phase Effects 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 208000010496 Heart Arrest Diseases 0.000 description 2
• 208000013875 Heart injury Diseases 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
• 241000208278 Hyoscyamus Species 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 102000004388 Interleukin-4 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 2
• 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
• 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 2
• 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 2
• 241000186779 Listeria monocytogenes Species 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 2
• 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 2
• LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
• 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
• 231100000678 Mycotoxin Toxicity 0.000 description 2
• 108010083674 Myelin Proteins Proteins 0.000 description 2
• 102000006386 Myelin Proteins Human genes 0.000 description 2
• 208000009525 Myocarditis Diseases 0.000 description 2
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
• 102100021010 Nucleolin Human genes 0.000 description 2
• 208000003435 Optic Neuritis Diseases 0.000 description 2
• 102000018886 Pancreatic Polypeptide Human genes 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 206010034464 Periarthritis Diseases 0.000 description 2
• 241000150350 Peribunyaviridae Species 0.000 description 2
• YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 208000012641 Pigmentation disease Diseases 0.000 description 2
• 101710195957 Platelet basic protein Proteins 0.000 description 2
• 102000004211 Platelet factor 4 Human genes 0.000 description 2
• 108090000778 Platelet factor 4 Proteins 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
• 206010037151 Psittacosis Diseases 0.000 description 2
• 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
• 206010063897 Renal ischaemia Diseases 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 208000036071 Rhinorrhea Diseases 0.000 description 2
• 206010039101 Rhinorrhoea Diseases 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 235000004443 Ricinus communis Nutrition 0.000 description 2
• 241000606695 Rickettsia rickettsii Species 0.000 description 2
• 102100032741 SET-binding protein Human genes 0.000 description 2
• 108050007079 Saposin Proteins 0.000 description 2
• 102000017852 Saposin Human genes 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 208000010513 Stupor Diseases 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
• 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 2
• 208000000491 Tendinopathy Diseases 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 108010074506 Transfer Factor Proteins 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 206010046851 Uveitis Diseases 0.000 description 2
• 208000009311 VIPoma Diseases 0.000 description 2
• 241000700647 Variola virus Species 0.000 description 2
• 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 2
• ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• PBNSPNYJYOYWTA-UHFFFAOYSA-N adamsite Chemical compound C1=CC=C2[As](Cl)C3=CC=CC=C3NC2=C1 PBNSPNYJYOYWTA-UHFFFAOYSA-N 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 239000013566 allergen Substances 0.000 description 2
• XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
• ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 2
• 208000003455 anaphylaxis Diseases 0.000 description 2
• XLJMAIOERFSOGZ-UHFFFAOYSA-N anhydrous cyanic acid Natural products OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 230000001773 anti-convulsant effect Effects 0.000 description 2
• 239000001961 anticonvulsive agent Substances 0.000 description 2
• 229960003965 antiepileptics Drugs 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 208000021328 arterial occlusion Diseases 0.000 description 2
• 206010003230 arteritis Diseases 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 229940091771 aspergillus fumigatus Drugs 0.000 description 2
• 229940065181 bacillus anthracis Drugs 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 230000002146 bilateral effect Effects 0.000 description 2
• 239000003150 biochemical marker Substances 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 229910052796 boron Inorganic materials 0.000 description 2
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
• WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
• 208000030303 breathing problems Diseases 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 235000013877 carbamide Nutrition 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000010307 cell transformation Effects 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 230000001886 ciliary effect Effects 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 210000000078 claw Anatomy 0.000 description 2
• 229960003920 cocaine Drugs 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 238000012790 confirmation Methods 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 230000001054 cortical effect Effects 0.000 description 2
• 229940109239 creatinine Drugs 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000007123 defense Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• YHHKGKCOLGRKKB-UHFFFAOYSA-N diphenylchlorarsine Chemical compound C=1C=CC=CC=1[As](Cl)C1=CC=CC=C1 YHHKGKCOLGRKKB-UHFFFAOYSA-N 0.000 description 2
• 239000000428 dust Substances 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 201000002491 encephalomyelitis Diseases 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 208000028104 epidemic louse-borne typhus Diseases 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 231100000321 erythema Toxicity 0.000 description 2
• 230000004992 fission Effects 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 230000004927 fusion Effects 0.000 description 2
• 229960003980 galantamine Drugs 0.000 description 2
• BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 2
• ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 210000000224 granular leucocyte Anatomy 0.000 description 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
• 230000009931 harmful effect Effects 0.000 description 2
• 230000002008 hemorrhagic effect Effects 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
• 125000001165 hydrophobic group Chemical group 0.000 description 2
• 208000018875 hypoxemia Diseases 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 238000011081 inoculation Methods 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 201000004614 iritis Diseases 0.000 description 2
• 210000003127 knee Anatomy 0.000 description 2
• 238000009940 knitting Methods 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 238000002386 leaching Methods 0.000 description 2
• 201000010260 leiomyoma Diseases 0.000 description 2
• 150000002617 leukotrienes Chemical class 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 238000002703 mutagenesis Methods 0.000 description 2
• 231100000350 mutagenesis Toxicity 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 239000002636 mycotoxin Substances 0.000 description 2
• 210000005012 myelin Anatomy 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 230000004112 neuroprotection Effects 0.000 description 2
• 230000000324 neuroprotective effect Effects 0.000 description 2
• 230000000508 neurotrophic effect Effects 0.000 description 2
• 229960002715 nicotine Drugs 0.000 description 2
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 108010044762 nucleolin Proteins 0.000 description 2
• 230000035764 nutrition Effects 0.000 description 2
• 235000016709 nutrition Nutrition 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 201000000901 ornithosis Diseases 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 201000011116 pancreatic cholera Diseases 0.000 description 2
• LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 2
• 239000004031 partial agonist Substances 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000010412 perfusion Effects 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 210000003800 pharynx Anatomy 0.000 description 2
• IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 description 2
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 230000019612 pigmentation Effects 0.000 description 2
• 210000002381 plasma Anatomy 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 230000002947 procoagulating effect Effects 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 230000002633 protecting effect Effects 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 230000000241 respiratory effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 206010039083 rhinitis Diseases 0.000 description 2
• 229940075118 rickettsia rickettsii Drugs 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 210000003497 sciatic nerve Anatomy 0.000 description 2
• DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 201000005113 shigellosis Diseases 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 208000020431 spinal cord injury Diseases 0.000 description 2
• 238000012453 sprague-dawley rat model Methods 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 230000035882 stress Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 201000004415 tendinitis Diseases 0.000 description 2
• MRMOZBOQVYRSEM-UHFFFAOYSA-N tetraethyllead Chemical compound CC[Pb](CC)(CC)CC MRMOZBOQVYRSEM-UHFFFAOYSA-N 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 239000002341 toxic gas Substances 0.000 description 2
• 231100000027 toxicology Toxicity 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000000472 traumatic effect Effects 0.000 description 2
• 206010061393 typhus Diseases 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 210000001215 vagina Anatomy 0.000 description 2
• 230000002227 vasoactive effect Effects 0.000 description 2
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• XLEKQZHPKBRJNB-SRBOSORUSA-N (2S)-3-sulfanylpyrrolidine-2-carboxylic acid Chemical compound SC1[C@@H](NCC1)C(=O)O XLEKQZHPKBRJNB-SRBOSORUSA-N 0.000 description 1
• DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
• KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• JGFMNFBZRAISGQ-UHFFFAOYSA-N (propan-2-yloxy)phosphinic acid Chemical class CC(C)OP(O)=O JGFMNFBZRAISGQ-UHFFFAOYSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical class CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
• PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
• KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
• GBNVXYXIRHSYEG-UHFFFAOYSA-N 1-chloro-2-ethylsulfanylethane Chemical compound CCSCCCl GBNVXYXIRHSYEG-UHFFFAOYSA-N 0.000 description 1
• YZBOZNXACBQJHI-UHFFFAOYSA-N 1-dichlorophosphoryloxyethane Chemical compound CCOP(Cl)(Cl)=O YZBOZNXACBQJHI-UHFFFAOYSA-N 0.000 description 1
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
• PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
• JJNZXLAFIPKXIG-UHFFFAOYSA-N 2-Chlorobenzylidenemalononitrile Chemical compound ClC1=CC=CC=C1C=C(C#N)C#N JJNZXLAFIPKXIG-UHFFFAOYSA-N 0.000 description 1
• KXKAXOZWSFAJTG-UHFFFAOYSA-N 2-[ethyl(fluoro)phosphoryl]oxypropane Chemical compound CCP(F)(=O)OC(C)C KXKAXOZWSFAJTG-UHFFFAOYSA-N 0.000 description 1
• QXISTPDUYKNPLU-UHFFFAOYSA-N 2-bromo-1,4-dimethylbenzene Chemical compound CC1=CC=C(C)C(Br)=C1 QXISTPDUYKNPLU-UHFFFAOYSA-N 0.000 description 1
• QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
• PJISLFCKHOHLLP-UHFFFAOYSA-N 2-diethoxyphosphorylsulfanyl-n,n-diethylethanamine Chemical compound CCOP(=O)(OCC)SCCN(CC)CC PJISLFCKHOHLLP-UHFFFAOYSA-N 0.000 description 1
• IVQOFBKHQCTVQV-UHFFFAOYSA-N 2-hydroxy-2,2-diphenylacetic acid 2-(diethylamino)ethyl ester Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 IVQOFBKHQCTVQV-UHFFFAOYSA-N 0.000 description 1
• MWFMGBPGAXYFAR-UHFFFAOYSA-N 2-hydroxy-2-methylpropanenitrile Chemical compound CC(C)(O)C#N MWFMGBPGAXYFAR-UHFFFAOYSA-N 0.000 description 1
• MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 1
• GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
• YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
• TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
• UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 1
• UWSONZCNXUSTKW-UHFFFAOYSA-N 4,5-Dimethylthiazole Chemical compound CC=1N=CSC=1C UWSONZCNXUSTKW-UHFFFAOYSA-N 0.000 description 1
• MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
• ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
• IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
• USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
• JMHFFDIMOUKDCZ-NTXHZHDSSA-N 61214-51-5 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 JMHFFDIMOUKDCZ-NTXHZHDSSA-N 0.000 description 1
• XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
• 108020005176 AU Rich Elements Proteins 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 206010000372 Accident at work Diseases 0.000 description 1
• 102100033639 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 208000010444 Acidosis Diseases 0.000 description 1
• 208000002874 Acne Vulgaris Diseases 0.000 description 1
• 101710159080 Aconitate hydratase A Proteins 0.000 description 1
• 101710159078 Aconitate hydratase B Proteins 0.000 description 1
• NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 208000004804 Adenomatous Polyps Diseases 0.000 description 1
• 206010001367 Adrenal insufficiency Diseases 0.000 description 1
• 208000009888 Adrenocortical Adenoma Diseases 0.000 description 1
• 229930195730 Aflatoxin Natural products 0.000 description 1
• XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
• 241000701386 African swine fever virus Species 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 241000588986 Alcaligenes Species 0.000 description 1
• 241001492267 Alcelaphine gammaherpesvirus 1 Species 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 241000710929 Alphavirus Species 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 206010060937 Amniotic cavity infection Diseases 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 206010002199 Anaphylactic shock Diseases 0.000 description 1
• 208000028185 Angioedema Diseases 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 206010002660 Anoxia Diseases 0.000 description 1
• 241000976983 Anoxia Species 0.000 description 1
• 206010003011 Appendicitis Diseases 0.000 description 1
• 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
• 241000239290 Araneae Species 0.000 description 1
• 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 1
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 241001106067 Atropa Species 0.000 description 1
• 229930003347 Atropine Natural products 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 241000711404 Avian avulavirus 1 Species 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 229910015900 BF3 Inorganic materials 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 206010062804 Basal cell naevus syndrome Diseases 0.000 description 1
• 208000011068 Bazex syndrome Diseases 0.000 description 1
• 208000034068 Bazex-Dupré-Christol syndrome Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102400000748 Beta-endorphin Human genes 0.000 description 1
• 101800005049 Beta-endorphin Proteins 0.000 description 1
• 101800003265 Beta-thromboglobulin Proteins 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
• 208000034200 Bolivian hemorrhagic fever Diseases 0.000 description 1
• 208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 108030001720 Bontoxilysin Proteins 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 241000283725 Bos Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000007198 Bovine Brucellosis Diseases 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 102400000967 Bradykinin Human genes 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 241000219198 Brassica Species 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• 206010006440 Bronchial obstruction Diseases 0.000 description 1
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• 201000007651 Brooke-Spiegler syndrome Diseases 0.000 description 1
• 241000589562 Brucella Species 0.000 description 1
• 241000589567 Brucella abortus Species 0.000 description 1
• 241001453380 Burkholderia Species 0.000 description 1
• 241000722910 Burkholderia mallei Species 0.000 description 1
• 241001136175 Burkholderia pseudomallei Species 0.000 description 1
• 206010006784 Burning sensation Diseases 0.000 description 1
• YMTDUCWDMRDNBN-UHFFFAOYSA-N C(C=C1)=CC=C1NC1=CC=CC=C1.Cl.[AsH3] Chemical compound C(C=C1)=CC=C1NC1=CC=CC=C1.Cl.[AsH3] YMTDUCWDMRDNBN-UHFFFAOYSA-N 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
• 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
• 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
• 102000001902 CC Chemokines Human genes 0.000 description 1
• 108010040471 CC Chemokines Proteins 0.000 description 1
• BLESYQCWVHUCTB-UHFFFAOYSA-N CP(O)(=S)OCCN Chemical compound CP(O)(=S)OCCN BLESYQCWVHUCTB-UHFFFAOYSA-N 0.000 description 1
• 101100394073 Caenorhabditis elegans hil-1 gene Proteins 0.000 description 1
• 101100069853 Caenorhabditis elegans hil-3 gene Proteins 0.000 description 1
• 102000055006 Calcitonin Human genes 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
• 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 206010051226 Campylobacter infection Diseases 0.000 description 1
• 241000282461 Canis lupus Species 0.000 description 1
• 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
• 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
• 241000700664 Capripoxvirus Species 0.000 description 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
• 206010007509 Cardiac amyloidosis Diseases 0.000 description 1
• 206010048610 Cardiotoxicity Diseases 0.000 description 1
• 208000000671 Carney triad Diseases 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 206010057248 Cell death Diseases 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• 108010014414 Chemokine CXCL2 Proteins 0.000 description 1
• 102000016951 Chemokine CXCL2 Human genes 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 241001647378 Chlamydia psittaci Species 0.000 description 1
• VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 208000008158 Chorioamnionitis Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 208000002691 Choroiditis Diseases 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
• 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
• 206010009192 Circulatory collapse Diseases 0.000 description 1
• 241000193403 Clostridium Species 0.000 description 1
• 102100030563 Coagulation factor XI Human genes 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
• 206010010539 Congenital megacolon Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 208000034656 Contusions Diseases 0.000 description 1
• 206010010947 Coordination abnormal Diseases 0.000 description 1
• 208000028006 Corneal injury Diseases 0.000 description 1
• 206010011219 Costochondritis Diseases 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 208000012609 Cowden disease Diseases 0.000 description 1
• 201000002847 Cowden syndrome Diseases 0.000 description 1
• 241001445332 Coxiella <snail> Species 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 1
• 244000241257 Cucumis melo Species 0.000 description 1
• 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
• 108010068192 Cyclin A Proteins 0.000 description 1
• 108010058546 Cyclin D1 Proteins 0.000 description 1
• 108010058544 Cyclin D2 Proteins 0.000 description 1
• 108010058545 Cyclin D3 Proteins 0.000 description 1
• 108090000257 Cyclin E Proteins 0.000 description 1
• 102000003909 Cyclin E Human genes 0.000 description 1
• 102100025191 Cyclin-A2 Human genes 0.000 description 1
• 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 101000972324 Cynodon dactylon Leaf protein Proteins 0.000 description 1
• 150000000782 D-glucoses Chemical class 0.000 description 1
• 206010011841 Dacryoadenitis acquired Diseases 0.000 description 1
• 208000001840 Dandruff Diseases 0.000 description 1
• 241000208296 Datura Species 0.000 description 1
• 206010011985 Decubitus ulcer Diseases 0.000 description 1
• 208000019505 Deglutition disease Diseases 0.000 description 1
• 206010012218 Delirium Diseases 0.000 description 1
• 208000001490 Dengue Diseases 0.000 description 1
• 206010012310 Dengue fever Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
• RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
• 102100024441 Dihydropyrimidinase-related protein 5 Human genes 0.000 description 1
• 108050002654 Dihydropyrimidinase-related protein 5 Proteins 0.000 description 1
• PGJBQBDNXAZHBP-UHFFFAOYSA-N Dimefox Chemical compound CN(C)P(F)(=O)N(C)C PGJBQBDNXAZHBP-UHFFFAOYSA-N 0.000 description 1
• 101100327242 Drosophila melanogaster CycE gene Proteins 0.000 description 1
• 208000001708 Dupuytren contracture Diseases 0.000 description 1
• 208000014094 Dystonic disease Diseases 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
• 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
• 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 1
• 206010014614 Encephalitis western equine Diseases 0.000 description 1
• 208000017701 Endocrine disease Diseases 0.000 description 1
• 208000004145 Endometritis Diseases 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 201000011275 Epicondylitis Diseases 0.000 description 1
• 108050004280 Epsilon toxin Proteins 0.000 description 1
• 241000588698 Erwinia Species 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 102100036509 Erythropoietin receptor Human genes 0.000 description 1
• 101710102442 Erythropoietin receptor Proteins 0.000 description 1
• 229940087983 Erythropoietin receptor agonist Drugs 0.000 description 1
• 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 208000009386 Experimental Arthritis Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• PNVJTZOFSHSLTO-UHFFFAOYSA-N Fenthion Chemical compound COP(=S)(OC)OC1=CC=C(SC)C(C)=C1 PNVJTZOFSHSLTO-UHFFFAOYSA-N 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 241000711950 Filoviridae Species 0.000 description 1
• 241000710781 Flaviviridae Species 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
• 235000016623 Fragaria vesca Nutrition 0.000 description 1
• 240000009088 Fragaria x ananassa Species 0.000 description 1
• 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
• 241000589602 Francisella tularensis Species 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
• 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
• 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 208000003098 Ganglion Cysts Diseases 0.000 description 1
• 208000000321 Gardner Syndrome Diseases 0.000 description 1
• 201000000628 Gas Gangrene Diseases 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
• 208000033694 Generalised erythema Diseases 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 208000005232 Glossitis Diseases 0.000 description 1
• 102400000321 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 108010015899 Glycopeptides Proteins 0.000 description 1
• 102000002068 Glycopeptides Human genes 0.000 description 1
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
• 208000031995 Gorlin syndrome Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 201000005708 Granuloma Annulare Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 206010056438 Growth hormone deficiency Diseases 0.000 description 1
• 206010056557 Gulf war syndrome Diseases 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• 206010061192 Haemorrhagic fever Diseases 0.000 description 1
• 206010019043 Hair follicle tumour benign Diseases 0.000 description 1
• 208000002927 Hamartoma Diseases 0.000 description 1
• 241000150562 Hantaan orthohantavirus Species 0.000 description 1
• BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 241000893570 Hendra henipavirus Species 0.000 description 1
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
• 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
• 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 description 1
• 208000004592 Hirschsprung disease Diseases 0.000 description 1
• 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 101000801359 Homo sapiens Acetylcholinesterase Proteins 0.000 description 1
• 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 1
• 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
• 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
• 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
• 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
• 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
• 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
• 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
• 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 1
• 101000653679 Homo sapiens Translationally-controlled tumor protein Proteins 0.000 description 1
• 241000701806 Human papillomavirus Species 0.000 description 1
• 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
• 101710091977 Hydrophobin Proteins 0.000 description 1
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 208000031814 IgA Vasculitis Diseases 0.000 description 1
• 208000004619 Inert Gas Narcosis Diseases 0.000 description 1
• 208000009773 Insulin Coma Diseases 0.000 description 1
• 102100026720 Interferon beta Human genes 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000003814 Interleukin-10 Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 102000003815 Interleukin-11 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 102100039897 Interleukin-5 Human genes 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 102100021592 Interleukin-7 Human genes 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 102000000585 Interleukin-9 Human genes 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 206010022822 Intravascular haemolysis Diseases 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 201000005807 Japanese encephalitis Diseases 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 208000036232 King Evil Diseases 0.000 description 1
• 208000003140 Kyasanur forest disease Diseases 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• 150000008540 L-glutamines Chemical class 0.000 description 1
• XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 208000009612 Laryngismus Diseases 0.000 description 1
• 201000008197 Laryngitis Diseases 0.000 description 1
• 206010023891 Laryngospasm Diseases 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 206010024612 Lipoma Diseases 0.000 description 1
• 102000003820 Lipoxygenases Human genes 0.000 description 1
• 108090000128 Lipoxygenases Proteins 0.000 description 1
• 206010024641 Listeriosis Diseases 0.000 description 1
• 241000609846 Lumpy skin disease virus Species 0.000 description 1
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
• 201000005027 Lynch syndrome Diseases 0.000 description 1
• VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
• 241000282553 Macaca Species 0.000 description 1
• 208000001344 Macular Edema Diseases 0.000 description 1
• 206010025415 Macular oedema Diseases 0.000 description 1
• 239000005949 Malathion Substances 0.000 description 1
• 208000002720 Malnutrition Diseases 0.000 description 1
• 241001115401 Marburgvirus Species 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 206010027146 Melanoderma Diseases 0.000 description 1
• 241000209295 Melanoderma Species 0.000 description 1
• 102100039373 Membrane cofactor protein Human genes 0.000 description 1
• 241001643857 Menangle virus Species 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 206010027417 Metabolic acidosis Diseases 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
• NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 241000700627 Monkeypox virus Species 0.000 description 1
• 208000010164 Multifocal Choroiditis Diseases 0.000 description 1
• 208000006876 Multiple Endocrine Neoplasia Type 2b Diseases 0.000 description 1
• 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
• 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
• 101100273648 Mus musculus Ccna2 gene Proteins 0.000 description 1
• 101100059444 Mus musculus Ccnb1 gene Proteins 0.000 description 1
• 101000851936 Mus musculus Endothelial PAS domain-containing protein 1 Proteins 0.000 description 1
• 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
• UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
• 241000282341 Mustela putorius furo Species 0.000 description 1
• 241000204025 Mycoplasma capricolum Species 0.000 description 1
• 241000202936 Mycoplasma mycoides Species 0.000 description 1
• 241000123119 Mycoplasma mycoides subsp. capri Species 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 208000006423 Myocardial Contusions Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• FBWADIKARMIWNM-UHFFFAOYSA-N N-3,5-dichloro-4-hydroxyphenyl-1,4-benzoquinone imine Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1N=C1C=CC(=O)C=C1 FBWADIKARMIWNM-UHFFFAOYSA-N 0.000 description 1
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
• 206010028748 Nasal obstruction Diseases 0.000 description 1
• 206010051606 Necrotising colitis Diseases 0.000 description 1
• 206010028885 Necrotising fasciitis Diseases 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 206010058119 Neurogenic shock Diseases 0.000 description 1
• 206010072359 Neuromyotonia Diseases 0.000 description 1
• 206010029379 Neutrophilia Diseases 0.000 description 1
• 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
• 241000526636 Nipah henipavirus Species 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
• 208000011623 Obstructive Lung disease Diseases 0.000 description 1
• 208000021957 Ocular injury Diseases 0.000 description 1
• 206010030094 Odynophagia Diseases 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 208000011448 Omsk hemorrhagic fever Diseases 0.000 description 1
• 208000030768 Optic nerve injury Diseases 0.000 description 1
• 208000025157 Oral disease Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000020971 Osgood-Schlatter disease Diseases 0.000 description 1
• 206010031149 Osteitis Diseases 0.000 description 1
• 201000009859 Osteochondrosis Diseases 0.000 description 1
• 101100112680 Ostreococcus tauri CycD gene Proteins 0.000 description 1
• 208000005141 Otitis Diseases 0.000 description 1
• 101150012195 PREB gene Proteins 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 208000033952 Paralysis flaccid Diseases 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 108090000445 Parathyroid hormone Proteins 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 206010034038 Parotitis Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000002141 Pellagra Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 101800001386 Peptide II Proteins 0.000 description 1
• 108010084214 Peptide PHI Proteins 0.000 description 1
• 239000000132 Peptide PHI Substances 0.000 description 1
• 108010071384 Peptide T Proteins 0.000 description 1
• 101800005164 Peptide V Proteins 0.000 description 1
• 229940122985 Peptide agonist Drugs 0.000 description 1
• 208000010886 Peripheral nerve injury Diseases 0.000 description 1
• 201000007100 Pharyngitis Diseases 0.000 description 1
• 201000000239 Phlebotomus fever Diseases 0.000 description 1
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 201000005746 Pituitary adenoma Diseases 0.000 description 1
• 206010061538 Pituitary tumour benign Diseases 0.000 description 1
• 208000010332 Plantar Fasciitis Diseases 0.000 description 1
• 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
• 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
• 206010035742 Pneumonitis Diseases 0.000 description 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
• 208000003971 Posterior uveitis Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000004210 Pressure Ulcer Diseases 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102100036197 Prosaposin Human genes 0.000 description 1
• 101710152403 Prosaposin Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 108091008109 Pseudogenes Proteins 0.000 description 1
• 102000057361 Pseudogenes Human genes 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 206010037423 Pulmonary oedema Diseases 0.000 description 1
• 241000442474 Pulsatilla vulgaris Species 0.000 description 1
• 206010037596 Pyelonephritis Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
• 241000238711 Pyroglyphidae Species 0.000 description 1
• 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
• 101710105008 RNA-binding protein Proteins 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 208000003782 Raynaud disease Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 108020005091 Replication Origin Proteins 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 206010038687 Respiratory distress Diseases 0.000 description 1
• 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
• 201000007737 Retinal degeneration Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 206010038926 Retinopathy hypertensive Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 240000000528 Ricinus communis Species 0.000 description 1
• 241000606697 Rickettsia prowazekii Species 0.000 description 1
• 241000606726 Rickettsia typhi Species 0.000 description 1
• 241000711897 Rinderpest morbillivirus Species 0.000 description 1
• 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 230000018199 S phase Effects 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 241000736032 Sabia <angiosperm> Species 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 208000007893 Salpingitis Diseases 0.000 description 1
• 240000006075 Sapindus trifoliatus Species 0.000 description 1
• DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
• 241000217239 Schizotrypanum Species 0.000 description 1
• 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• 241000700665 Sheeppox virus Species 0.000 description 1
• 108010079723 Shiga Toxin Proteins 0.000 description 1
• 241000607768 Shigella Species 0.000 description 1
• 206010040550 Shigella infections Diseases 0.000 description 1
• 206010040576 Shock hypoglycaemic Diseases 0.000 description 1
• 208000028990 Skin injury Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 206010041329 Somatostatinoma Diseases 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 241000269319 Squalius cephalus Species 0.000 description 1
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• 208000007107 Stomach Ulcer Diseases 0.000 description 1
• 241001504624 Streptopelia Species 0.000 description 1
• 208000036038 Subretinal fibrosis Diseases 0.000 description 1
• 102000019197 Superoxide Dismutase Human genes 0.000 description 1
• 108010012715 Superoxide dismutase Proteins 0.000 description 1
• 206010042658 Sweat gland tumour Diseases 0.000 description 1
• 206010042674 Swelling Diseases 0.000 description 1
• 241000709710 Swine vesicular disease virus Species 0.000 description 1
• 208000005400 Synovial Cyst Diseases 0.000 description 1
• BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
• 102000003691 T-Type Calcium Channels Human genes 0.000 description 1
• 108090000030 T-Type Calcium Channels Proteins 0.000 description 1
• IDCBOTIENDVCBQ-UHFFFAOYSA-N TEPP Chemical compound CCOP(=O)(OCC)OP(=O)(OCC)OCC IDCBOTIENDVCBQ-UHFFFAOYSA-N 0.000 description 1
• YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 description 1
• 208000002240 Tennis Elbow Diseases 0.000 description 1
• 208000004760 Tenosynovitis Diseases 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• 241000032211 Terebra Species 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 244000145580 Thalia geniculata Species 0.000 description 1
• 235000012419 Thalia geniculata Nutrition 0.000 description 1
• KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
• 208000026317 Tietze syndrome Diseases 0.000 description 1
• 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
• 206010044314 Tracheobronchitis Diseases 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 102100022972 Transcription factor AP-2-alpha Human genes 0.000 description 1
• 101710189834 Transcription factor AP-2-alpha Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 102100029887 Translationally-controlled tumor protein Human genes 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 208000030470 Trigger Finger disease Diseases 0.000 description 1
• 206010044654 Trigger finger Diseases 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 244000098338 Triticum aestivum Species 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 208000034784 Tularaemia Diseases 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102000018594 Tumour necrosis factor Human genes 0.000 description 1
• 108050007852 Tumour necrosis factor Proteins 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 102400000757 Ubiquitin Human genes 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
• 208000006593 Urologic Neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000006374 Uterine Cervicitis Diseases 0.000 description 1
• 206010046798 Uterine leiomyoma Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 201000008100 Vaginitis Diseases 0.000 description 1
• 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 1
• 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 1
• 241000711975 Vesicular stomatitis virus Species 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 241000607598 Vibrio Species 0.000 description 1
• 241000607626 Vibrio cholerae Species 0.000 description 1
• 206010047400 Vibrio infections Diseases 0.000 description 1
• 241000107360 Vincetoxicum glaucescens Species 0.000 description 1
• BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical class ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
• 208000028227 Viral hemorrhagic fever Diseases 0.000 description 1
• VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 1
• 201000005806 Western equine encephalitis Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 208000003152 Yellow Fever Diseases 0.000 description 1
• 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
• JPKKQJKQTPNWTR-BRYCGAMXSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1 JPKKQJKQTPNWTR-BRYCGAMXSA-N 0.000 description 1
• FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
• VEPPHSZWQFLVPA-UHFFFAOYSA-N [S].C(=C)Cl Chemical compound [S].C(=C)Cl VEPPHSZWQFLVPA-UHFFFAOYSA-N 0.000 description 1
• PJVJTCIRVMBVIA-JTQLQIEISA-N [dimethylamino(ethoxy)phosphoryl]formonitrile Chemical compound CCO[P@@](=O)(C#N)N(C)C PJVJTCIRVMBVIA-JTQLQIEISA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 230000009102 absorption Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
• 229960004373 acetylcholine Drugs 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 230000036982 action potential Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 150000001263 acyl chlorides Chemical class 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 208000018234 adnexal spiradenoma/cylindroma of a sweat gland Diseases 0.000 description 1
• 208000015234 adrenal cortex adenoma Diseases 0.000 description 1
• 201000003354 adrenal cortical adenoma Diseases 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000005409 aflatoxin Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 230000008369 airway response Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
• 208000008445 altitude sickness Diseases 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 230000004099 anaerobic respiration Effects 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 244000000054 animal parasite Species 0.000 description 1
• 230000007953 anoxia Effects 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 230000001088 anti-asthma Effects 0.000 description 1
• 230000001078 anti-cholinergic effect Effects 0.000 description 1
• 230000001387 anti-histamine Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 239000000924 antiasthmatic agent Substances 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 210000002376 aorta thoracic Anatomy 0.000 description 1
• 208000007474 aortic aneurysm Diseases 0.000 description 1
• 206010002906 aortic stenosis Diseases 0.000 description 1
• 210000001765 aortic valve Anatomy 0.000 description 1
• OEYOHULQRFXULB-UHFFFAOYSA-N arsenic trichloride Chemical compound Cl[As](Cl)Cl OEYOHULQRFXULB-UHFFFAOYSA-N 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 150000001504 aryl thiols Chemical class 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
• 229960000396 atropine Drugs 0.000 description 1
• 229960002028 atropine sulfate Drugs 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 229940125717 barbiturate Drugs 0.000 description 1
• HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 210000000270 basal cell Anatomy 0.000 description 1
• 229960001498 benactyzine Drugs 0.000 description 1
• CJPQIRJHIZUAQP-MRXNPFEDSA-N benalaxyl-M Chemical compound CC=1C=CC=C(C)C=1N([C@H](C)C(=O)OC)C(=O)CC1=CC=CC=C1 CJPQIRJHIZUAQP-MRXNPFEDSA-N 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 210000000013 bile duct Anatomy 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 238000010876 biochemical test Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 206010072959 birdshot chorioretinopathy Diseases 0.000 description 1
• JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 description 1
• 201000001531 bladder carcinoma Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 206010005159 blepharospasm Diseases 0.000 description 1
• 230000000744 blepharospasm Effects 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 239000003114 blood coagulation factor Substances 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 210000004155 blood-retinal barrier Anatomy 0.000 description 1
• 230000004378 blood-retinal barrier Effects 0.000 description 1
• 208000003836 bluetongue Diseases 0.000 description 1
• 208000018339 bone inflammation disease Diseases 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 230000036471 bradycardia Effects 0.000 description 1
• 208000006218 bradycardia Diseases 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• 208000025698 brain inflammatory disease Diseases 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 1
• 150000001649 bromium compounds Chemical class 0.000 description 1
• GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
• 210000000621 bronchi Anatomy 0.000 description 1
• 229940056450 brucella abortus Drugs 0.000 description 1
• 201000006824 bubonic plague Diseases 0.000 description 1
• 229940074375 burkholderia mallei Drugs 0.000 description 1
• 230000009172 bursting Effects 0.000 description 1
• 235000013844 butane Nutrition 0.000 description 1
• NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical compound CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 238000001354 calcination Methods 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 235000009120 camo Nutrition 0.000 description 1
• 201000004927 campylobacteriosis Diseases 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 1
• 229960002504 capsaicin Drugs 0.000 description 1
• 230000021235 carbamoylation Effects 0.000 description 1
• QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
• IYRWEQXVUNLMAY-UHFFFAOYSA-N carbonyl fluoride Chemical compound FC(F)=O IYRWEQXVUNLMAY-UHFFFAOYSA-N 0.000 description 1
• JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 206010007625 cardiogenic shock Diseases 0.000 description 1
• 230000002612 cardiopulmonary effect Effects 0.000 description 1
• 231100000259 cardiotoxicity Toxicity 0.000 description 1
• OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000003532 cataractogenesis Effects 0.000 description 1
• 230000034196 cell chemotaxis Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000004709 cell invasion Effects 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• 208000025434 cerebellar degeneration Diseases 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 206010008323 cervicitis Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 235000005607 chanvre indien Nutrition 0.000 description 1
• 239000013000 chemical inhibitor Substances 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 230000035606 childbirth Effects 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• 238000005660 chlorination reaction Methods 0.000 description 1
• KNSWNNXPAWSACI-UHFFFAOYSA-N chlorine pentafluoride Chemical compound FCl(F)(F)(F)F KNSWNNXPAWSACI-UHFFFAOYSA-N 0.000 description 1
• YGZSVWMBUCGDCV-UHFFFAOYSA-N chloro(methyl)silane Chemical compound C[SiH2]Cl YGZSVWMBUCGDCV-UHFFFAOYSA-N 0.000 description 1
• JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
• LFHISGNCFUNFFM-UHFFFAOYSA-N chloropicrin Chemical compound [O-][N+](=O)C(Cl)(Cl)Cl LFHISGNCFUNFFM-UHFFFAOYSA-N 0.000 description 1
• KNVLCWQKYHCADB-UHFFFAOYSA-N chlorosulfonyloxymethane Chemical compound COS(Cl)(=O)=O KNVLCWQKYHCADB-UHFFFAOYSA-N 0.000 description 1
• 235000019219 chocolate Nutrition 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 208000003167 cholangitis Diseases 0.000 description 1
• 201000001352 cholecystitis Diseases 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• 210000003737 chromaffin cell Anatomy 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 108010088797 cibinetide Proteins 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 229960005132 cisapride Drugs 0.000 description 1
• DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
• DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
• 238000009643 clonogenic assay Methods 0.000 description 1
• 231100000096 clonogenic assay Toxicity 0.000 description 1
• 201000003486 coccidioidomycosis Diseases 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 239000000039 congener Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 108050003126 conotoxin Proteins 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 230000030944 contact inhibition Effects 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 230000009193 crawling Effects 0.000 description 1
• MLUCVPSAIODCQM-NSCUHMNNSA-N crotonaldehyde Chemical compound C\C=C\C=O MLUCVPSAIODCQM-NSCUHMNNSA-N 0.000 description 1
• MLUCVPSAIODCQM-UHFFFAOYSA-N crotonaldehyde Natural products CC=CC=O MLUCVPSAIODCQM-UHFFFAOYSA-N 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• SNTRKUOVAPUGAY-UHFFFAOYSA-N cyclosarin Chemical compound CP(F)(=O)OC1CCCCC1 SNTRKUOVAPUGAY-UHFFFAOYSA-N 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 150000001944 cysteine derivatives Chemical class 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 201000003146 cystitis Diseases 0.000 description 1
• 230000002559 cytogenic effect Effects 0.000 description 1
• 230000021953 cytokinesis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 201000004400 dacryoadenitis Diseases 0.000 description 1
• 208000012208 de Quervain disease Diseases 0.000 description 1
• 238000005034 decoration Methods 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 208000025729 dengue disease Diseases 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000000586 desensitisation Methods 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 125000003963 dichloro group Chemical group Cl* 0.000 description 1
• GIKLTQKNOXNBNY-UHFFFAOYSA-N dichloro(2-chloroethenyl)arsane Chemical class ClC=C[As](Cl)Cl GIKLTQKNOXNBNY-UHFFFAOYSA-N 0.000 description 1
• LQSFEOMOHFPNEB-UHFFFAOYSA-N dichloro(ethyl)arsane Chemical compound CC[As](Cl)Cl LQSFEOMOHFPNEB-UHFFFAOYSA-N 0.000 description 1
• FRNHPBDNOSCJNW-UHFFFAOYSA-N dichloro-ethyl-sulfanylidene-$l^{5}-phosphane Chemical compound CCP(Cl)(Cl)=S FRNHPBDNOSCJNW-UHFFFAOYSA-N 0.000 description 1
• FAXIJTUDSBIMHY-UHFFFAOYSA-N diethoxy-(2-ethylsulfanylethoxy)-sulfanylidene-$l^{5}-phosphane;1-diethoxyphosphorylsulfanyl-2-ethylsulfanylethane Chemical compound CCOP(=O)(OCC)SCCSCC.CCOP(=S)(OCC)OCCSCC FAXIJTUDSBIMHY-UHFFFAOYSA-N 0.000 description 1
• JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 229940099170 ditropan Drugs 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 208000000718 duodenal ulcer Diseases 0.000 description 1
• 208000019258 ear infection Diseases 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 208000030172 endocrine system disease Diseases 0.000 description 1
• 238000009261 endocrine therapy Methods 0.000 description 1
• 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 230000008497 endothelial barrier function Effects 0.000 description 1
• 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 231100000655 enterotoxin Toxicity 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 201000009580 eosinophilic pneumonia Diseases 0.000 description 1
• 201000010063 epididymitis Diseases 0.000 description 1
• 230000001037 epileptic effect Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 230000008378 epithelial damage Effects 0.000 description 1
• 208000010932 epithelial neoplasm Diseases 0.000 description 1
• 210000003013 erythroid precursor cell Anatomy 0.000 description 1
• 235000019441 ethanol Nutrition 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
• 229960003750 ethyl chloride Drugs 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• MFFXVVHUKRKXCI-UHFFFAOYSA-N ethyl iodoacetate Chemical compound CCOC(=O)CI MFFXVVHUKRKXCI-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 239000004060 excitotoxin Substances 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 238000004880 explosion Methods 0.000 description 1
• 210000002603 extrahepatic bile duct Anatomy 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 239000004744 fabric Substances 0.000 description 1
• 229960002428 fentanyl Drugs 0.000 description 1
• IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 210000003811 finger Anatomy 0.000 description 1
• 235000019688 fish Nutrition 0.000 description 1
• 208000028331 flaccid paralysis Diseases 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• HXRXYYVPIQXCPA-UHFFFAOYSA-N fluoro-methyl-propan-2-yloxy-sulfanylidene-$l^{5}-phosphane Chemical compound CC(C)OP(C)(F)=S HXRXYYVPIQXCPA-UHFFFAOYSA-N 0.000 description 1
• 201000002904 focal dystonia Diseases 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 229940118764 francisella tularensis Drugs 0.000 description 1
• 201000010603 frozen shoulder Diseases 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 208000024386 fungal infectious disease Diseases 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• 201000005917 gastric ulcer Diseases 0.000 description 1
• 201000000052 gastrinoma Diseases 0.000 description 1
• 230000007387 gliosis Effects 0.000 description 1
• 210000004704 glottis Anatomy 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 229960004275 glycolic acid Drugs 0.000 description 1
• 125000003147 glycosyl group Chemical group 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
• 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 210000003780 hair follicle Anatomy 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 210000002837 heart atrium Anatomy 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 208000025750 heavy chain disease Diseases 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 210000000777 hematopoietic system Anatomy 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 239000011487 hemp Substances 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• VUNCWTMEJYMOOR-UHFFFAOYSA-N hexachlorocyclopentadiene Chemical compound ClC1=C(Cl)C(Cl)(Cl)C(Cl)=C1Cl VUNCWTMEJYMOOR-UHFFFAOYSA-N 0.000 description 1
• 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 229940046533 house dust mites Drugs 0.000 description 1
• 102000043557 human IFNG Human genes 0.000 description 1
• 102000055151 human KITLG Human genes 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
• 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
• 201000008980 hyperinsulinism Diseases 0.000 description 1
• 230000003463 hyperproliferative effect Effects 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 201000001948 hypertensive retinopathy Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 208000021822 hypotensive Diseases 0.000 description 1
• 230000001077 hypotensive effect Effects 0.000 description 1
• 230000002631 hypothermal effect Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 230000000642 iatrogenic effect Effects 0.000 description 1
• HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 1
• OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 description 1
• AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 description 1
• 208000009326 ileitis Diseases 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 239000012133 immunoprecipitate Substances 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 208000016290 incoordination Diseases 0.000 description 1
• 150000002475 indoles Chemical class 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 229960003971 influenza vaccine Drugs 0.000 description 1
• 239000002917 insecticide Substances 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000003914 insulin secretion Effects 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 230000010438 iron metabolism Effects 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
• 210000001847 jaw Anatomy 0.000 description 1
• VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
• 229950006874 kainic acid Drugs 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• 201000010666 keratoconjunctivitis Diseases 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 208000022013 kidney Wilms tumor Diseases 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 208000036546 leukodystrophy Diseases 0.000 description 1
• 238000011694 lewis rat Methods 0.000 description 1
• 208000010325 limbic encephalitis Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 231100000863 loss of memory Toxicity 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 201000010453 lymph node cancer Diseases 0.000 description 1
• 201000007227 lymph node tuberculosis Diseases 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 201000010230 macular retinal edema Diseases 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 229960000453 malathion Drugs 0.000 description 1
• 241001515942 marmosets Species 0.000 description 1
• 208000004396 mastitis Diseases 0.000 description 1
• 208000008585 mastocytosis Diseases 0.000 description 1
• 230000028161 membrane depolarization Effects 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 201000011475 meningoencephalitis Diseases 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000006609 metabolic stress Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 229960001797 methadone Drugs 0.000 description 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960002683 methohexital Drugs 0.000 description 1
• XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
• 150000003956 methylamines Chemical class 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• VXRMBBLRHSRVDK-UHFFFAOYSA-N methyldichloroarsine Chemical compound C[As](Cl)Cl VXRMBBLRHSRVDK-UHFFFAOYSA-N 0.000 description 1
• 238000004452 microanalysis Methods 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 208000022499 mismatch repair cancer syndrome Diseases 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 210000004115 mitral valve Anatomy 0.000 description 1
• 208000005907 mitral valve insufficiency Diseases 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 210000002161 motor neuron Anatomy 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 231100000017 mucous membrane irritation Toxicity 0.000 description 1
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• 229940087004 mustargen Drugs 0.000 description 1
• 210000003007 myelin sheath Anatomy 0.000 description 1
• 210000003887 myelocyte Anatomy 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• RHFUXPCCELGMFC-UHFFFAOYSA-N n-(6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl)-n-phenylmethoxyacetamide Chemical compound OC1C(C)(C)OC2=CC=C(C#N)C=C2C1N(C(=O)C)OCC1=CC=CC=C1 RHFUXPCCELGMFC-UHFFFAOYSA-N 0.000 description 1
• IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical class CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 210000001989 nasopharynx Anatomy 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
• 201000007970 necrotizing fasciitis Diseases 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 208000029522 neoplastic syndrome Diseases 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 210000003360 nephrocyte Anatomy 0.000 description 1
• 208000009928 nephrosis Diseases 0.000 description 1
• 231100001027 nephrosis Toxicity 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 210000003757 neuroblast Anatomy 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000001703 neuroimmune Effects 0.000 description 1
• 239000003176 neuroleptic agent Substances 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 201000002165 neuroretinitis Diseases 0.000 description 1
• 108010070612 neurotoxic esterase Proteins 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 1
• 238000011587 new zealand white rabbit Methods 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
• 231100001160 nonlethal Toxicity 0.000 description 1
• 230000006911 nucleation Effects 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 229960004429 obidoxime Drugs 0.000 description 1
• KZCOBXFFBQJQHH-UHFFFAOYSA-N octane-1-thiol Chemical compound CCCCCCCCS KZCOBXFFBQJQHH-UHFFFAOYSA-N 0.000 description 1
• 206010030306 omphalitis Diseases 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 210000003300 oropharynx Anatomy 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• ZIFJVJZWVSPZLE-UHFFFAOYSA-N oxo-[[1-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxymethyl]pyridin-4-ylidene]methyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COCN1C=CC(=C[NH+]=O)C=C1 ZIFJVJZWVSPZLE-UHFFFAOYSA-N 0.000 description 1
• 229960005434 oxybutynin Drugs 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 208000021255 pancreatic insulinoma Diseases 0.000 description 1
• 201000007407 panuveitis Diseases 0.000 description 1
• 201000005675 papillary conjunctivitis Diseases 0.000 description 1
• 230000001769 paralizing effect Effects 0.000 description 1
• 208000011869 paraneoplastic limbic encephalitis Diseases 0.000 description 1
• WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 210000003899 penis Anatomy 0.000 description 1
• IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
• 108010091742 peptide F Proteins 0.000 description 1
• 108010091718 peptide L Proteins 0.000 description 1
• 108010091867 peptide P Proteins 0.000 description 1
• 108010091858 peptide Q Proteins 0.000 description 1
• RJSZPKZQGIKVAU-UXBJKDEOSA-N peptide f Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C(C)C)C(C)C)C1=CC=CC=C1 RJSZPKZQGIKVAU-UXBJKDEOSA-N 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• 210000003516 pericardium Anatomy 0.000 description 1
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 206010034674 peritonitis Diseases 0.000 description 1
• 201000010076 persian gulf syndrome Diseases 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• UDHDFEGCOJAVRE-UHFFFAOYSA-N phenyldichloroarsine Chemical compound Cl[As](Cl)C1=CC=CC=C1 UDHDFEGCOJAVRE-UHFFFAOYSA-N 0.000 description 1
• HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
• 229940067157 phenylhydrazine Drugs 0.000 description 1
• 208000001297 phlebitis Diseases 0.000 description 1
• JIRJHEXNDQBKRZ-UHFFFAOYSA-N phosgene oxime Chemical compound ON=C(Cl)Cl JIRJHEXNDQBKRZ-UHFFFAOYSA-N 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• OBCUTHMOOONNBS-UHFFFAOYSA-N phosphorus pentafluoride Chemical compound FP(F)(F)(F)F OBCUTHMOOONNBS-UHFFFAOYSA-N 0.000 description 1
• FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
• LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
• 230000002186 photoactivation Effects 0.000 description 1
• 238000005424 photoluminescence Methods 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 208000021310 pituitary gland adenoma Diseases 0.000 description 1
• 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 208000008423 pleurisy Diseases 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920006324 polyoxymethylene Polymers 0.000 description 1
• 208000015768 polyposis Diseases 0.000 description 1
• 239000013259 porous coordination polymer Substances 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 230000001686 pro-survival effect Effects 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• QQKDTTWZXHEGAQ-UHFFFAOYSA-N propyl carbonochloridate Chemical compound CCCOC(Cl)=O QQKDTTWZXHEGAQ-UHFFFAOYSA-N 0.000 description 1
• OANVFVBYPNXRLD-UHFFFAOYSA-M propyromazine bromide Chemical compound [Br-].C12=CC=CC=C2SC2=CC=CC=C2N1C(=O)C(C)[N+]1(C)CCCC1 OANVFVBYPNXRLD-UHFFFAOYSA-M 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 230000001185 psoriatic effect Effects 0.000 description 1
• 208000005333 pulmonary edema Diseases 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• 229940005657 pyrophosphoric acid Drugs 0.000 description 1
• 230000000191 radiation effect Effects 0.000 description 1
• 239000012857 radioactive material Substances 0.000 description 1
• 208000006934 radiodermatitis Diseases 0.000 description 1
• 230000001950 radioprotection Effects 0.000 description 1
• 230000007420 reactivation Effects 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000015766 regulation of tumor necrosis factor biosynthetic process Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000008085 renal dysfunction Effects 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 210000004994 reproductive system Anatomy 0.000 description 1
• 208000017443 reproductive system disease Diseases 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 238000005316 response function Methods 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 108010004093 retinal S antigen peptide M Proteins 0.000 description 1
• 239000000790 retinal pigment Substances 0.000 description 1
• 210000001957 retinal vein Anatomy 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 208000004124 rheumatic heart disease Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229940046939 rickettsia prowazekii Drugs 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 201000004700 rosacea Diseases 0.000 description 1
• 201000005404 rubella Diseases 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 1
• RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 229960002646 scopolamine Drugs 0.000 description 1
• LACQPOBCQQPVIT-SEYKEWMNSA-N scopolamine hydrobromide trihydrate Chemical compound O.O.O.Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 LACQPOBCQQPVIT-SEYKEWMNSA-N 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 210000001732 sebaceous gland Anatomy 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 230000001624 sedative effect Effects 0.000 description 1
• SPVXKVOXSXTJOY-UHFFFAOYSA-N selane Chemical compound [SeH2] SPVXKVOXSXTJOY-UHFFFAOYSA-N 0.000 description 1
• 229910000058 selane Inorganic materials 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 235000015170 shellfish Nutrition 0.000 description 1
• 239000000238 shellfish toxin Substances 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 231100000075 skin burn Toxicity 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 238000010181 skin prick test Methods 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical class [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 1
• 239000002689 soil Substances 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 238000003836 solid-state method Methods 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 230000009295 sperm incapacitation Effects 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 230000035322 succinylation Effects 0.000 description 1
• 238000010613 succinylation reaction Methods 0.000 description 1
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
• 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
• OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
• 210000000106 sweat gland Anatomy 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 230000001360 synchronised effect Effects 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 208000006379 syphilis Diseases 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 description 1
• NNCGPRGCYAWTAF-UHFFFAOYSA-N tellurium hexafluoride Chemical compound F[Te](F)(F)(F)(F)F NNCGPRGCYAWTAF-UHFFFAOYSA-N 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• XOOGZRUBTYCLHG-UHFFFAOYSA-N tetramethyllead Chemical compound C[Pb](C)(C)C XOOGZRUBTYCLHG-UHFFFAOYSA-N 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 description 1
• 229960002784 thioridazine Drugs 0.000 description 1
• 108010050939 thrombocytin Proteins 0.000 description 1
• 210000003813 thumb Anatomy 0.000 description 1
• 206010043688 thyroid adenoma Diseases 0.000 description 1
• HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
• 229940098465 tincture Drugs 0.000 description 1
• XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
• DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
• RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
• 208000025093 tonsil carcinoma Diseases 0.000 description 1
• 206010044008 tonsillitis Diseases 0.000 description 1
• 210000000515 tooth Anatomy 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000133 toxic exposure Toxicity 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000012301 transgenic model Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 208000009174 transverse myelitis Diseases 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 description 1
• 208000016811 trichoblastoma Diseases 0.000 description 1
• FQFKTKUFHWNTBN-UHFFFAOYSA-N trifluoro-$l^{3}-bromane Chemical compound FBr(F)F FQFKTKUFHWNTBN-UHFFFAOYSA-N 0.000 description 1
• 208000030629 trigger thumb Diseases 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 230000001810 trypsinlike Effects 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• NXHILIPIEUBEPD-UHFFFAOYSA-H tungsten hexafluoride Chemical compound F[W](F)(F)(F)(F)F NXHILIPIEUBEPD-UHFFFAOYSA-H 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 235000000112 undernutrition Nutrition 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 229960001055 uracil mustard Drugs 0.000 description 1
• JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• 208000000143 urethritis Diseases 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 210000002229 urogenital system Anatomy 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 229940118696 vibrio cholerae Drugs 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 210000003905 vulva Anatomy 0.000 description 1
• 208000002003 vulvitis Diseases 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1